3. To determine whether CYT107 administration increases the vaccine -induced antigen- specific antibody immune response s to PAP and PA2024 IgM and IgG response to PAP and PA2024 will be measured by standard ELISA. 4. To quantify the effects of CYT107 on T -cell diversity The T -cell repertoire will be characterized by T -cell receptor (TCR) deep sequencing and the analysis will be done with the Immunoseq Analyzer software (Harlan Robins, PhD , with Adaptive Biotechnologies, Seattle). 5. To assess the effects of CYT107 on the immune competence of patients with advanced prostate cancer Bystander antigen specific immune responses will be assessed to other ongoing and nascent antitumor responses (e. g., PRAME, NY -ESO -1 and/or p53), additional tumor antigens specific to prostate cancer (e.g., PSA and/or PSMA), and memory viral responses (influenza A and CEF) using the IFNg ELISPOT assay. Thymic function will be assessed by measuring levels of T -cell r eceptor rearrangement DNA excision circles (TRECs).